Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times. - Wikidata - wikimedia - TriplyDB

Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times.

Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times.

http://www.wikidata.org/entity/Q35154103

about

CT Appearance of Hepatocellular Carcinoma after Locoregional Treatments: A Comprehensive Review Management of unresectable intrahepatic cholangiocarcinoma: how do we decide among the various liver-directed treatments?Decade in review-hepatocellular carcinoma: HCC-subtypes, stratification and sorafenib.Chemoembolization and radioembolization for metastatic disease to the liver: available data and future studies.Intra-arterial therapy for advanced intrahepatic cholangiocarcinoma: a multi-institutional analysis.Comparative evaluation of percutaneous laser and radiofrequency ablation in patients with HCC smaller than 4 cm.Hepatocellular carcinoma: clinical frontiers and perspectives.Radioembolization for neuroendocrine liver metastases: safety, imaging, and long-term outcomes Increasing disparity in waitlist mortality rates with increased model for end-stage liver disease scores for candidates with hepatocellular carcinoma versus candidates without hepatocellular carcinoma.Extrahepatic metastases occur in a minority of hepatocellular carcinoma patients treated with locoregional therapies: analyzing patterns of progression in 285 patients.Alpha-fetoprotein response correlates with EASL response and survival in solitary hepatocellular carcinoma treated with transarterial therapies: a subgroup analysis.Liver cancer: Approaching a personalized care.Intraprocedural 3D Quantification of Lipiodol Deposition on Cone-Beam CT Predicts Tumor Response After Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma.Comparison of combination therapies in the management of hepatocellular carcinoma: transarterial chemoembolization with radiofrequency ablation versus microwave ablation.Impact of cytolysis following transarterial chemoembolization for hepatocellular carcinoma Does the Degree of Hepatocellular Carcinoma Tumor Necrosis following Transarterial Chemoembolization Impact Patient Survival?Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept Unresectable hepatocellular carcinoma: MR imaging after intraarterial therapy. Part I. Identification and validation of volumetric functional response criteria Interreader and inter-test agreement in assessing treatment response following transarterial embolization for hepatocellular carcinoma Chemoembolization and radioembolization for hepatocellular carcinoma.Impact of sarcopenia on outcomes following intra-arterial therapy of hepatic malignancies.Alternative Response Criteria (Choi, European association for the study of the liver, and modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib.Toward a standardized system for hepatocellular carcinoma diagnosis using computed tomography and MRI.Assessment of treatment response in hepatocellular carcinoma: a review of the literature.Imaging tumor response following liver-directed intra-arterial therapy.Treatment of intermediate-stage hepatocellular carcinoma.Evolution from WHO to EASL and mRECIST for hepatocellular carcinoma: considerations for tumor response assessment.Clinical outcomes of Y90 radioembolization for recurrent hepatocellular carcinoma following curative resection.Predictive factors for complete response of chemoembolization with drug-eluting beads (DEB-TACE) for hepatocellular carcinoma.Transarterial chemoembolization vs. radiofrequency ablation for the treatment of single hepatocellular carcinoma 2 cm or smaller.Sustained safety and efficacy of extended-shelf-life (90)Y glass microspheres: long-term follow-up in a 134-patient cohort.18F-fluorodeoxyglucose PET/CT predicts tumour progression after transarterial chemoembolization in hepatocellular carcinoma.Pictorial essay: imaging findings following Y90 radiation segmentectomy for hepatocellular carcinoma.Chemoembolization with doxorubicin-eluting beads for unresectable hepatocellular carcinoma: five-year survival analysis.Percutaneous Treatment of Localized Infiltrative Hepatocellular Carcinoma Developing on Cirrhosis.Efficacy of RECIST and mRECIST criteria as prognostic factors in patients undergoing repeated iodized oil chemoembolization of intermediate stage hepatocellular carcinoma.Radiologic response to transcatheter hepatic arterial chemoembolization and clinical outcomes in patients with hepatocellular carcinoma.Transarterial chemoembolization as a substitute to radiofrequency ablation for treating Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma.Radioembolisation bei fortgeschrittenem hepatozellulärem Karzinom Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: A phase 2 study

P2860

Q26770014-4B9FB180-B393-4F1D-8AA8-69B4F82F4BE9 Q33621522-F0619B9E-CAE2-4E0A-9235-DA23A6152B3B Q33926379-97180479-BC3A-47FE-8675-BD129CBFB6EC Q34330617-861C38CD-D8C5-4414-BBC7-CD6DB7604881 Q34654186-A7FBE9F3-D0D1-4553-BE4D-1EB60D31C94B Q35052932-1ED451D5-94C9-4EE1-A162-13F7F0E2BD70 Q35112053-D7B98712-3BFC-4353-A163-E15874FFA236 Q35815482-4EE3E676-16F2-457B-A5F0-881804A1F73A Q35869964-704B0D54-7CD9-4791-9315-F880FE112F8E Q35877902-A83E1660-0711-40F7-92DF-D4BD5CA59ED8 Q35894925-6DDA4323-5080-46FF-882A-56A724F350B7 Q35903794-2DC64438-F619-4D59-99C8-365CF83D10B0 Q36296750-E018A7F3-48AC-4CFD-83DE-99D6F3CD38FF Q36345251-89C0D833-DBF2-41D1-8C71-D57360B64918 Q36582556-D5CA1CF7-CD77-481A-99DE-431EE48ABC8C Q36582635-258BCE37-534E-47C0-9333-22E60A4D5BB1 Q36920698-4A6E9199-FA1E-41C1-8425-D4ED2987D3C4 Q37039550-EADA0203-11D3-4BBD-90EF-8C0CA4654845 Q37143017-B04C58FA-EA52-40CC-B941-D900180B38C3 Q37238192-6D1982C1-2994-4351-89A1-798EA79F0AD0 Q37695686-825AA9A1-7761-451C-907F-8637E89CD151 Q37698184-EA37C883-E4E4-4381-9696-FB4BB8EA069E Q38085067-FB3A21E9-51FF-41E4-9EA1-F47FC43F3DE9 Q38110321-C09F8696-789B-4D99-AB90-55519184019B Q38117579-DEB979F3-864C-4B04-925F-F3E06F2CF7F0 Q38236876-A9A944B7-8984-4C07-9AB5-A74B4A9307C6 Q38265024-9268DAF9-E0C4-452B-AD79-4B05A10A0334 Q40091767-7F915A5A-72C0-436A-AC82-D1914C406A42 Q41235807-E1373361-8E0D-4519-8F7E-644AB1E2BC3C Q42212138-20AB6A11-21C8-4257-8142-471292114AC7 Q46151344-270B2E5B-8C19-496F-A56C-C09B1CE590C6 Q46775794-00DE0473-B685-4C17-AC63-FD9E099BCB13 Q48285755-242046CF-89D6-47EF-93E1-A93FA2CB2286 Q53160804-D7117074-90A7-41F1-B20D-DB9697363156 Q53220257-289534F4-A5BD-451B-BADD-61781B9AF99D Q53246536-986CBBEF-E7CC-481B-8636-1013C5025E75 Q53321440-6B8835FD-126F-44B6-9B66-1593A5F44A74 Q55256355-CB74C79E-A88A-4F2A-8D9D-4FC901429015 Q57079477-E740B032-8FFA-4837-93C8-DD321934E7B5 Q57763422-7D69978F-CF20-49CD-8115-9822714DF459

P2860

Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times.

http://www.wikidata.org/entity/Q35154103

description

2011 nî lūn-bûn

@nan

2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Radiographic response to locor ...... edicts patient survival times.

@ast

Radiographic response to locor ...... edicts patient survival times.

@en

type

label

Radiographic response to locor ...... edicts patient survival times.

@ast

Radiographic response to locor ...... edicts patient survival times.

@en

prefLabel

Radiographic response to locor ...... edicts patient survival times.

@ast

Radiographic response to locor ...... edicts patient survival times.

@en

P1433

Q35154103-EF49CFE8-25D3-4F05-9A8D-45D94444D129

P1476

Q35154103-8E855307-98C6-4021-9CE8-622F0E51D4AF

P2093

Q35154103-0C2A86A3-F45A-454A-A050-ADCFBA32435B

Q35154103-13845068-5FCA-40E7-AFAC-AF5BF53A5F39

Q35154103-1635F057-5A97-4265-8E45-11C110F44466

Q35154103-20BF1559-5F73-4692-B237-291C81827EF6

Q35154103-3A647FA8-6A6B-4022-89AC-10DCF5FF05B3

Q35154103-4A2C7C02-D76C-4C11-904E-A4A12B91D649

Q35154103-66E847AE-2F35-42A1-B4AE-4FBE86611AB8

Q35154103-812F6467-A5E6-4084-80FD-63C0AF007E40

Q35154103-81E29C99-06BE-4622-9626-9C3F24C7EAD5

Q35154103-9494EE50-E3F8-4306-887E-3312F5011860

P2860

Q35154103-04F02C00-4405-4C57-9734-5D239F31A356

Q35154103-0755B29D-BE9E-4845-8B21-C6A125E3A957

Q35154103-0A9236A3-D743-4A94-8749-3C6E9FC98EAB

Q35154103-1FD8925B-589D-4A8D-9611-FCFC5AEFBA18

Q35154103-2E07D245-4477-4761-A42D-07BDF48D5970

Q35154103-31D291B1-6FDD-4FC5-9EF1-659DE65FF9ED

Q35154103-3B00F4DE-8890-4D0D-8487-6C295DFF4B65

Q35154103-495B268B-A379-4E7D-AAA3-B0D779D5407F

Q35154103-4A714D88-F0DB-442B-B135-2A248F507C4A

Q35154103-4A7CBD9C-71EC-4D82-862F-FBEC7FBE302A

P304

Q35154103-718F326F-0248-46CD-BCCC-42DDC24A6943

P31

Q35154103-73A1F489-9123-42D1-8C24-DA2AE04ED0D9

P356

Q35154103-A16FA0C0-45EF-422F-974F-F5C1BEA5221A

P407

Q35154103-1C13E9D0-1CA7-422A-84A4-0F59AC50C6C6

P433

Q35154103-DE7CB91D-D4C1-44EA-A480-2C366087450B

P478

Q35154103-B4F981A2-EBE9-4B25-9196-A59F622DC4C1

P50

Q35154103-2072F3A6-57A9-41D2-A7EE-BDBA34BFE25D

Q35154103-59CB5278-6825-42A0-BFE2-C32AA91C21FF

P577

Q35154103-4BBEC610-187A-4218-816B-E7EE2E6E5B81

P5875

Q35154103-98ACEE89-5E89-49E8-98A4-41943D6A777B

P698

Q35154103-4AD2CFAC-834A-40BB-A39F-4957ED4CF2E4

P921

Q35154103-198BEC14-FE97-4F1B-93F3-6F508AD45783

P932

Q35154103-7C44359E-6E72-4794-ADBD-A8A84EC4950C

P356

J.GASTRO.2011.04.054

P1433

Gastroenterology

P1476

Radiographic response to locor ...... edicts patient survival times.

@en

P2093

Ahsun Riaz

http://www.w3.org/2001/XMLSchema#string

Al B Benson

http://www.w3.org/2001/XMLSchema#string

Edward Wang

http://www.w3.org/2001/XMLSchema#string

Frank H Miller

http://www.w3.org/2001/XMLSchema#string

Karen Marshall

http://www.w3.org/2001/XMLSchema#string

Kent T Sato

http://www.w3.org/2001/XMLSchema#string

Khairuddin Memon

http://www.w3.org/2001/XMLSchema#string

Laura Kulik

http://www.w3.org/2001/XMLSchema#string

Mary F Mulcahy

http://www.w3.org/2001/XMLSchema#string

Michael Abecassis

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics, 2002

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Sorafenib in advanced hepatocellular carcinoma

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival

Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver

Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial

Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma

Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis

Primary liver cancer: worldwide incidence and trends

P304

526-35, 535.e1-2

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1053/J.GASTRO.2011.04.054

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

141

http://www.w3.org/2001/XMLSchema#string

P50

Vanessa L. Gates

P577

2011-04-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51210756

http://www.w3.org/2001/XMLSchema#string

P698

21664356

http://www.w3.org/2001/XMLSchema#string

P921

P932

3152626

http://www.w3.org/2001/XMLSchema#string